• Eric Kaplovitch, Joseph R Shaw, and James Douketis.
• Department of Medicine, University Health Network and Sinai Health System, University of Toronto, 585 University Avenue, 7th Floor, Room 739, Toronto, Ontario M5G 2N2, Canada. Electronic address: eric.kaplovitch@uhn.ca.
• Crit Care Clin. 2020 Jul 1; 36 (3): 465-480.

AbstractAcute pulmonary embolism (PE) is associated with high in-hospital morbidity and mortality, both via cardiorespiratory decompensation and the bleeding complications of treatment. Thrombolytic therapy can be life-saving in those with high-risk PE, but requires careful patient selection. Patients with PE and systemic arterial hypotension ("massive PE") should receive thrombolytic therapy unless severe contraindications are present. Patients with PE and right ventricular dysfunction/injury, but without hypotension ("submassive PE"), should be considered for thrombolysis on a case-by-case basis, considering bleeding risk, cardiac biomarkers, echocardiography, and most importantly, clinical status.Copyright © 2020 Elsevier Inc. All rights reserved.

28 keywords...

hide…